Navigation Links
QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
Date:1/9/2012

HILDEN and BERLIN, Germany, January 9, 2012 /PRNewswire/ --

  • Collaboration to create molecular test assessing a person's risk for latent TB progressing to active TB, enabling early treatment and disease outbreak prevention
  • QIAGEN strengthening its leading infectious disease portfolio with development of DNA-/RNA-based test that complements QuantiFERON-TB Gold test for latent TB
  • New assay will use whole blood transcription profiling - a new diagnostic technology developed at the Max Planck Institute's Department of Immunology
  • New molecular test to be run on the QIAsymphony modular automation platform

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt: Prime Standard: QIA) and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime. Financial terms were not disclosed.

Approximately one-third of the world's population is estimated to be infected with Mycobacterium tuberculosis, but do not have active tuberculosis. The identification and treatment of these individuals is critical to controlling this disease since approximately 5-10% of latent TB patients are at risk for developing active TB during their lifetime, particularly those with weakened immune systems.  

As a follow-up to those who test positive for latent TB, this new test will be designed to enable early treatment before reactivation of the TB disease, when it becomes contagious and causes life-threatening respiratory illnesses and other diseases.

This new mol
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
2. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
3. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
4. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
5. QIAGEN Acquires Exclusive Licence for Key PI3K gene
6. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
7. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
8. Plexus Awarded Development Contract With QIAGEN
9. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
10. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
11. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... ZIONA, Israel , July 28, ... OTC:CQPTY), a regenerative medicine company utilizing its proprietary ... announced that Shomrat Shurtz has been appointed Senior ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) ... years of experience in marketing, regulatory and business ...
(Date:7/27/2015)... and FRANKLIN, Tenn. , July ... premier provider of health care services and one ... U.S., today announced that its parent company and ... definitive agreement with Medical Properties Trust, Inc. ("MPT") ... Capella for $900 million in cash.  The transaction is expected ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn of ... in the EU. For instance, it surpassed the EUR 106 million mark (in value ... 2010. Germany is a major producer, while Italy is a key consumer. , ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... an information technology and Web products and services provider ... announced today that St. Luke,s Hospital & Health Network ... remote 24/7/365 IT infrastructure monitoring from CareTech,s Healthcare Infrastructure ... and monitoring of data, systems and applications located in ...
... innovative medical imaging informatics company, today announced the commercial ... Edition. Following the April release of their first commercial ... commercial version of their widely accepted DICOM ImageServer software, ... With the release of the PACS, Team Edition, ...
... windows which, thanks to a nanocoating, adjust their level ... to save energy; novel diagnostic methods and tailor-made nano-medicines ... one hand, can be used to make very efficient ... pheromones, protect vineyards from insect attack; new nanostructured materials ...
Cached Biology Technology:St. Luke's Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure 2St. Luke's Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure 3ClearCanvas Releases First Commercial Version of Widely Used PACS; Integrated RIS/PACS to Follow 2A world without nano? Soon hard to imagine 2A world without nano? Soon hard to imagine 3
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... 2008 American Society for Microbiology (ASM) Siemens ... presented to Adrian M. Zelazny, Staff Scientist, ... Institutes of Health (NIH). This award recognizes ... antimicrobial therapy. Dr. Zelazny is honored ...
... of supercomputers have hardware set up not just for ... seemingly random data. And now, a multi-institutional group of ... for these supercomputers. Applications include anywhere complex webs of ... grid stability to complex biological networks. The ...
... from infecting other cells and triggering their destruction by ... HIV-infected individuals but eventually peters out. To find out ... Infectious Diseases examined the cells that make the antibodies, ... that HIV gradually depletes the numbers of healthy, functional ...
Cached Biology News:Multithreaded supercomputer seeks software for data-intensive computing 2Multithreaded supercomputer seeks software for data-intensive computing 3
... cell-based assays utilize the membrane-permeant ester ... negatively charged fluorescent beta-lactamase substrates, CCF2 ... enter the cell, where cleavage by ... into their negatively charged forms, thereby ...
...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
...
Biology Products: